{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:40Z","timestamp":1757618140761,"version":"3.44.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>As life expectancy increases, the incidence of hip fractures and the demand for total hip arthroplasties (THA) are expected to rise. This demographic shift poses significant challenges, particularly in managing post-operative complications such as venous thromboembolism (VTE), a major cause of mortality. Despite advancements, the effectiveness of various anticoagulants, in preventing VTE post-THA or hip fracture surgery remains unclear due to conflicting study results. This study aims to thoroughly evaluate the efficacy and safety of fondaparinux in patients undergoing elective THA or hip fracture surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This review adhered to PRISMA guidelines. Inclusion criteria targeted studies on hip surgery patients treated with fondaparinux versus placebo or other anticoagulants. Data was collected from three major databases in November 2024 using the PICOS framework, focusing on following outcomes: venous thromboembolism, mortality, and bleeding rates. Meta-analysis utilized Review Manager 5.4, and applying a fixed-effects model unless significant heterogeneity (I\u00b2 \u2265 50%) was detected. Sensitivity and subgroup analyses further refined the results based on surgery type and control groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nineteen studies (<jats:italic>n<\/jats:italic>\u2009=\u200932534) were included in the meta-analysis. Fondaparinux significantly reduced the incidence of VTE compared to controls (OR 0.43, 95% CI 0.31 to 0.61) and low molecular weight heparins (LMWHs) (OR 0.55, 95% CI 0.41 to 0.74). The incidence of distal deep vein thrombosis (DVT) was also lower in fondaparinux group compared to LMWHs (OR 0.43, 95% CI 0.31 to 0.62). Proximal DVT showed a significant reduction overall (OR 0.33, 95% CI 0.15 to 0.75) in fondaparinux group, with no significant difference compared to enoxaparin specifically (OR 0.48, 95% CI 0.20 to 1.17). Additionally, there were no substantial differences in clinically significant bleeding. The average costs (euros, pounds and\/or dollars) per patient per thromboembolic event at 90 days were lower in the fondaparinux group compared to enoxaparin, both in patients undergoing elective THA (132 vs. 216) and hip fracture surgery (339 vs. 518).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Based on the results of this meta-analysis, fondaparinux significantly reduced VTE and DVT incidence compared to LMWHs in patients undergoing elective THA and hip fracture surgery, with a similar incidence of clinically significant bleeding. Additionally, it demonstrated lower costs per thrombsoembolic event per patient than enoxaparin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13018-025-05950-6","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:52:57Z","timestamp":1748479977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of fondaparinux in elective total hip arthroplasty and hip fracture surgery: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-198X","authenticated-orcid":false,"given":"Gonzalo","family":"Mariscal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jos\u00e9","family":"Tarazona-Santabalbina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-5766","authenticated-orcid":false,"given":"Oliver","family":"Marin-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Rotavista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Arroyo","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Estrella Fern\u00e1ndez","family":"de Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"G\u00f3mez-Vallejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"5950_CR1","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.regg.2024.101571","volume":"60","author":"D Villal\u00f3n-Rubio","year":"2024","unstructured":"Villal\u00f3n-Rubio D, Garc\u00eda-Tercero E, L\u00f3pez-G\u00f3mez J, Gonz\u00e1lez H, Belenguer-Varea \u00c1, Cunha-P\u00e9rez C, et al. Exploring factors influencing delirium incidence: insights from the Alzira cohort study, 2012\u20132021. Rev Esp Geriatr Gerontol. 2024;60(1):101571. https:\/\/doi.org\/10.1016\/j.regg.2024.101571.","journal-title":"Rev Esp Geriatr Gerontol"},{"issue":"6","key":"5950_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.joca.2014.04.009","volume":"22","author":"C Pabinger","year":"2014","unstructured":"Pabinger C, Geissler A. Utilization rates of hip arthroplasty in OECD countries. Osteoarthritis Cartilage. 2014;22(6):734\u201341. https:\/\/doi.org\/10.1016\/j.joca.2014.04.009.","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"5950_CR3","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/medicina58101314","volume":"58","author":"N Maffulli","year":"2022","unstructured":"Maffulli N, Aicale R. Proximal femoral fractures in the elderly: A few things to know, and some to forget. Med (Kaunas). 2022;58(10):1314. https:\/\/doi.org\/10.3390\/medicina58101314.","journal-title":"Med (Kaunas)"},{"issue":"1","key":"5950_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1302\/0301-620X.106B1.BJJ-2023-0740","volume":"106\u2013B","author":"E Harris","year":"2024","unstructured":"Harris E, Clement N, MacLullich A, Farrow L. The impact of an ageing population on future increases in hip fracture burden. Bone Joint J. 2024;106\u2013B(1):62\u20138. https:\/\/doi.org\/10.1302\/0301-620X.106B1.BJJ-2023-0740.","journal-title":"Bone Joint J"},{"issue":"3","key":"5950_CR5","first-page":"139","volume":"13","author":"LM Kwong","year":"2004","unstructured":"Kwong LM. Hip fracture and venous thromboembolism in the elderly. J Surg Orthop Adv. 2004;13(3):139\u201348.","journal-title":"J Surg Orthop Adv"},{"issue":"1","key":"5950_CR6","doi-asserted-by":"publisher","first-page":"103142","DOI":"10.1016\/j.otsr.2021.103142","volume":"108","author":"P Beauchamp-Chalifour","year":"2022","unstructured":"Beauchamp-Chalifour P, Belzile \u00c9L, Michael R, Langevin V, Gaudreau N, Normandeau N, et al. The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients. Orthop Traumatol Surg Res. 2022;108(1):103142. https:\/\/doi.org\/10.1016\/j.otsr.2021.103142.","journal-title":"Orthop Traumatol Surg Res"},{"issue":"9","key":"5950_CR7","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/j.1538-7836.2005.01545.x","volume":"3","author":"N Rosencher","year":"2005","unstructured":"Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM, ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005;3(9):2006\u201314. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01545.x.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"5950_CR8","doi-asserted-by":"publisher","first-page":"e016784","DOI":"10.1161\/JAHA.120.016784","volume":"9","author":"KA Martin","year":"2020","unstructured":"Martin KA, Molsberry R, Cuttica MJ, Desai KR, Schimmel DR, Khan SS. Time trends in pulmonary embolism mortality rates in the united States, 1999 to 2018. J Am Heart Assoc. 2020;9(17):e016784. https:\/\/doi.org\/10.1161\/JAHA.120.016784.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"5950_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00776-010-0011-5","volume":"16","author":"S Sasaki","year":"2011","unstructured":"Sasaki S, Miyakoshi N, Matsuura H, Saito H, Nakanishi T, Kudo Y, et al. Prospective study on the efficacies of Fondaparinux and Enoxaparin in preventing venous thromboembolism after hip fracture surgery. J Orthop Sci. 2011;16(1):64\u201370. https:\/\/doi.org\/10.1007\/s00776-010-0011-5.","journal-title":"J Orthop Sci"},{"key":"5950_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/ORR.S431372","volume":"15","author":"A Haibier","year":"2023","unstructured":"Haibier A, Yusufu A, Lin H, Kayierhan A, Abudukelimu Y, Abudurexiti T. Efficacy and safety study of Low-Molecular-Weight heparin and Fondaparinux sodium after hip arthroplasty: A retrospective cohort study. Orthop Res Rev. 2023;15:253\u201361. https:\/\/doi.org\/10.2147\/ORR.S431372.","journal-title":"Orthop Res Rev"},{"issue":"2","key":"5950_CR11","first-page":"185","volume":"24","author":"L Wang","year":"2024","unstructured":"Wang L, Xu Z, Zhang L. A comparison between Fondaparinux sodium and Low-Molecular-Weight heparin in preventing patients undergoing hip replacement from deep vein thrombosis. J Musculoskelet Neuronal Interact. 2024;24(2):185\u201391.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"9319","key":"5950_CR12","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","volume":"359","author":"MR Lassen","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative Fondaparinux versus preoperative Enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359(9319):1715\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(02)08652-X.","journal-title":"Lancet"},{"issue":"6","key":"5950_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1080\/17453674.2017.1361131","volume":"88","author":"M Hur","year":"2017","unstructured":"Hur M, Park SK, Koo CH, Jung ED, Kang P, Kim WH, et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017;88(6):634\u201341. https:\/\/doi.org\/10.1080\/17453674.2017.1361131.","journal-title":"Acta Orthop"},{"issue":"2","key":"5950_CR14","doi-asserted-by":"publisher","first-page":"e32635","DOI":"10.1097\/MD.0000000000032635","volume":"102","author":"Z Huang","year":"2023","unstructured":"Huang Z, Xu X, Xu D, Zhao P, Zou M. Efficacy of 11 anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and network meta-analysis. Med (Baltim). 2023;102(2):e32635. https:\/\/doi.org\/10.1097\/MD.0000000000032635.","journal-title":"Med (Baltim)"},{"key":"5950_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"5950_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"5950_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"5950_CR18","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Wiley; 2019.","DOI":"10.1002\/9781119536604"},{"key":"5950_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66:173\u201383.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"5950_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","volume":"163","author":"BI Eriksson","year":"2003","unstructured":"Eriksson BI, Lassen MR. PENTasaccharide in HIp-FRActure surgery plus investigators. Duration of prophylaxis against venous thromboembolism with Fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163(11):1337\u201342. https:\/\/doi.org\/10.1001\/archinte.163.11.1337.","journal-title":"Arch Intern Med"},{"issue":"18","key":"5950_CR21","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011100","volume":"345","author":"BI Eriksson","year":"2001","unstructured":"Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Steering committee of the pentasaccharide in Hip-Fracture surgery study. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345(18):1298\u2013304. https:\/\/doi.org\/10.1056\/NEJMoa011100.","journal-title":"N Engl J Med"},{"key":"5950_CR22","doi-asserted-by":"publisher","unstructured":"Turpie AG, Bauer KA, Eriksson BI, Lassen MR, PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359(9319):1721-6. https:\/\/doi.org\/10.1016\/S0140-6736(02)08648-8. Erratum in: Lancet 2002;360(9339):1102.","DOI":"10.1016\/S0140-6736(02)08648-8"},{"issue":"2","key":"5950_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1302\/0301-620X.93B2.25795","volume":"93","author":"R Yokote","year":"2011","unstructured":"Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J Bone Joint Surg Br. 2011;93(2):251\u20136. https:\/\/doi.org\/10.1302\/0301-620X.93B2.25795.","journal-title":"J Bone Joint Surg Br"},{"issue":"4","key":"5950_CR24","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar4616","volume":"16","author":"K Migita","year":"2014","unstructured":"Migita K, Bito S, Nakamura M, Miyata S, Saito M, Kakizaki H, et al. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study. Arthritis Res Ther. 2014;16(4):R154. https:\/\/doi.org\/10.1186\/ar4616.","journal-title":"Arthritis Res Ther"},{"key":"5950_CR25","doi-asserted-by":"publisher","unstructured":"Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop. 2008;32(4):443\u2013\u200951. https:\/\/doi.org\/10.1007\/s00264-007-0360-7. Epub 2007 Apr 28. PMID: 17468868.","DOI":"10.1007\/s00264-007-0360-7"},{"issue":"2","key":"5950_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10165-011-0496-6","volume":"22","author":"H Kawaji","year":"2012","unstructured":"Kawaji H, Ishii M, Tamaki Y, Hamasaki M, Ishikawa H, Sasaki K, et al. Postoperative prophylactic effect of Fondaparinux for prevention of deep venous thrombosis after cemented total hip replacement: a comparative study. Mod Rheumatol. 2012;22(2):216\u201322. https:\/\/doi.org\/10.1007\/s10165-011-0496-6.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"5950_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12893-024-02440-0","volume":"24","author":"X Gao","year":"2024","unstructured":"Gao X, Jin X, Huang R, Li Z, Zhang H, Fan P. Comparison of efficacy of Nadroparin and Fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients. BMC Surg. 2024;24(1):162. https:\/\/doi.org\/10.1186\/s12893-024-02440-0.","journal-title":"BMC Surg"},{"issue":"1","key":"5950_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/17453674.2011.652886","volume":"83","author":"Y Yukizawa","year":"2012","unstructured":"Yukizawa Y, Inaba Y, Watanabe S, Yajima S, Kobayashi N, Ishida T, Iwamoto N, et al. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop. 2012;83(1):14\u201321. https:\/\/doi.org\/10.3109\/17453674.2011.652886.","journal-title":"Acta Orthop"},{"issue":"6","key":"5950_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00776-014-0607-2","volume":"19","author":"Y Tsuda","year":"2014","unstructured":"Tsuda Y, Yasunaga H, Horiguchi H, Fushimi K, Kawano H, Tanaka S. Effects of Fondaparinux on pulmonary embolism following hemiarthroplasty for femoral neck fracture: a retrospective observational study using the Japanese diagnosis procedure combination database. J Orthop Sci. 2014;19(6):991\u20136. https:\/\/doi.org\/10.1007\/s00776-014-0607-2.","journal-title":"J Orthop Sci"},{"key":"5950_CR30","doi-asserted-by":"publisher","unstructured":"Okada Y, Endo H, Mitani S, Fujiwara K, Tetsunaga T, Kagawa Y et al. Venous thromboembolism after total hip arthroplasty diagnosed by enhanced computed tomography:comparison of selective thromboprophylaxis and no thromboprophylaxis. Acta Med Okayama. 2015;69(4):205\u2013\u200912. doi: 10.18926\/AMO\/53556. Erratum in: Acta Med Okayama. 2015;69(5):325. https:\/\/doi.org\/10.18926\/AMO\/53680","DOI":"10.18926\/AMO\/53680"},{"issue":"6","key":"5950_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1179\/acb.2004.050","volume":"59","author":"L Annemans","year":"2004","unstructured":"Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriel S, et al. Cost consequence analysis of Fondaparinux versus Enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin Belg. 2004;59(6):346\u201357. https:\/\/doi.org\/10.1179\/acb.2004.050.","journal-title":"Acta Clin Belg"},{"key":"5950_CR32","doi-asserted-by":"publisher","unstructured":"Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of Fondaparinux compared with Enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 2006 Mar-Apr;9(2):68\u201376. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00085.x","DOI":"10.1111\/j.1524-4733.2006.00085.x"},{"issue":"2","key":"5950_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00129784-200505020-00006","volume":"5","author":"A Bjorvatn","year":"2005","unstructured":"Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with Enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs. 2005;5(2):121\u201330. https:\/\/doi.org\/10.2165\/00129784-200505020-00006.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"5950_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10198-003-0175-4","volume":"4","author":"J Lundkvist","year":"2003","unstructured":"Lundkvist J, Bergqvist D, J\u00f6nsson B. Cost-effectiveness of Fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur J Health Econ. 2003;4(4):254\u201362. https:\/\/doi.org\/10.1007\/s10198-003-0175-4.","journal-title":"Eur J Health Econ"},{"key":"5950_CR35","doi-asserted-by":"publisher","first-page":"107424842211450","DOI":"10.1177\/10742484221145010","volume":"28","author":"RM Bauersachs","year":"2023","unstructured":"Bauersachs RM. Fondaparinux sodium: recent advances in the management of thrombosis. J Cardiovasc Pharmacol Ther. 2023;28:10742484221145010. https:\/\/doi.org\/10.1177\/10742484221145010.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10 Suppl 2","key":"5950_CR36","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.amjmed.2007.08.012","volume":"120","author":"AF Shorr","year":"2007","unstructured":"Shorr AF. The pharmacoeconomics of deep vein thrombosis treatment. Am J Med. 2007;120(10 Suppl 2):S35\u201341. https:\/\/doi.org\/10.1016\/j.amjmed.2007.08.012.","journal-title":"Am J Med"},{"issue":"1","key":"5950_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/wjnm.WJNM_13_17","volume":"17","author":"D Theerakulpisut","year":"2018","unstructured":"Theerakulpisut D, Wongsurawat N, Somboonporn C. Detection of lower limb deep vein thrombosis: comparison between radionuclide venography and venous ultrasonography. World J Nucl Med. 2018;17(1):27\u201333. https:\/\/doi.org\/10.4103\/wjnm.WJNM_13_17.","journal-title":"World J Nucl Med"},{"key":"5950_CR38","first-page":"497","volume":"42","author":"JD Douketis","year":"1996","unstructured":"Douketis JD, Ginsberg JS. Diagnosis of deep vein thrombosis. Can Fam Physician. 1996;42:497\u2013503.","journal-title":"Can Fam Physician"},{"issue":"12","key":"5950_CR39","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1055\/s-0042-1757200","volume":"122","author":"U Gurunathan","year":"2022","unstructured":"Gurunathan U, Barras M, McDougall C, Nandurkar H, Eley V. Obesity and the risk of venous thromboembolism after major lower limb orthopaedic surgery: A literature review. Thromb Haemost. 2022;122(12):1969\u201379. https:\/\/doi.org\/10.1055\/s-0042-1757200.","journal-title":"Thromb Haemost"},{"issue":"17","key":"5950_CR40","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2106\/JBJS.23.00146","volume":"105","author":"KC Liu","year":"2023","unstructured":"Liu KC, Piple AS, Richardson MK, Mayer LW, Mayfield CK, Christ AB, et al. Increased risk of venous thromboembolism in patients with postoperative Anemia after total joint arthroplasty: are transfusions to blame?? J Bone Joint Surg Am. 2023;105(17):1354\u201361. https:\/\/doi.org\/10.2106\/JBJS.23.00146.","journal-title":"J Bone Joint Surg Am"},{"issue":"8","key":"5950_CR41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00590-020-02712-4","volume":"30","author":"A Gu","year":"2020","unstructured":"Gu A, Wei C, Chen AZ, Malahias MA, Fassihi SC, Ast MP, et al. Operative time greater than 120 minutes is associated with increased pulmonary and thromboembolic complications following revision total hip arthroplasty. Eur J Orthop Surg Traumatol. 2020;30(8):1393\u2013400. https:\/\/doi.org\/10.1007\/s00590-020-02712-4.","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"12","key":"5950_CR42","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.arth.2014.05.018","volume":"29","author":"Y Zeng","year":"2014","unstructured":"Zeng Y, Shen B, Yang J, Zhou Z, Kang P, Pei F. Preoperative comorbidities as potential risk factors for venous thromboembolism after joint arthroplasty: a systematic review and meta-analysis of cohort and case-control studies. J Arthroplasty. 2014;29(12):2430\u20138. https:\/\/doi.org\/10.1016\/j.arth.2014.05.018.","journal-title":"J Arthroplasty"},{"issue":"10","key":"5950_CR43","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bcp.13663","volume":"84","author":"PJ Zufferey","year":"2018","unstructured":"Zufferey PJ, Ollier E, Delavenne X, Laporte S, Mismetti P, Duffull SB. Incidence and risk factors of major bleeding following major orthopaedic surgery with Fondaparinux thromboprophylaxis. A time-to-event analysis. Br J Clin Pharmacol. 2018;84(10):2242\u201351. https:\/\/doi.org\/10.1111\/bcp.13663.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5950_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1160\/TH10-02-0127","volume":"104","author":"X Delavenne","year":"2010","unstructured":"Delavenne X, Zufferey P, Baylot D, Nguyen P, Borg JY, Fontenay M, et al. Population pharmacokinetics of Fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost. 2010;104(2):252\u201360. https:\/\/doi.org\/10.1160\/TH10-02-0127.","journal-title":"Thromb Haemost"},{"issue":"1","key":"5950_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13018-021-02524-0","volume":"16","author":"M Quaranta","year":"2021","unstructured":"Quaranta M, Miranda L, Oliva F, Migliorini F, Pezzuti G, Maffulli N. Haemoglobin and transfusions in elderly patients with hip fractures: the effect of a dedicated orthogeriatrician. J Orthop Surg Res. 2021;16(1):387. https:\/\/doi.org\/10.1186\/s13018-021-02524-0.","journal-title":"J Orthop Surg Res"},{"issue":"4","key":"5950_CR46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.11138\/jts\/2016.4.4.214","volume":"4","author":"P DI Benedetto","year":"2017","unstructured":"DI Benedetto P, Vetrugno L, DE Franceschi D, Gisonni R, Causero A, Rocca GD. Patient compliance with new oral anticoagulants after major orthopaedic surgery: Rivaroxaban and Dabigatran compared with subcutaneous injection of Fondaparinux. Joints. 2017;4(4):214\u201321. https:\/\/doi.org\/10.11138\/jts\/2016.4.4.214.","journal-title":"Joints"},{"issue":"1","key":"5950_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10195-023-00742-2","volume":"25","author":"F Migliorini","year":"2024","unstructured":"Migliorini F, Maffulli N, Velaj E, Bell A, K\u00e4mmer D, Hildebrand F, et al. Antithrombotic prophylaxis following total hip arthroplasty: a level I bayesian network meta-analysis. J Orthop Traumatol. 2024;25(1):1. https:\/\/doi.org\/10.1186\/s10195-023-00742-2.","journal-title":"J Orthop Traumatol"},{"issue":"18","key":"5950_CR48","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/ajhp\/59.18.1750","volume":"59","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002;59(18):1750\u20134. https:\/\/doi.org\/10.1093\/ajhp\/59.18.1750.","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 2","key":"5950_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/00003088-200241002-00005","volume":"41","author":"C Ollier","year":"2002","unstructured":"Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, et al. Absence of interaction of Fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet. 2002;41(Suppl 2):31\u20137. https:\/\/doi.org\/10.2165\/00003088-200241002-00005.","journal-title":"Clin Pharmacokinet"},{"key":"5950_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5414\/ALX02422E","volume":"7","author":"K Brockow","year":"2023","unstructured":"Brockow K, Wurpts G, Trautmann A, Pf\u00fctzner W, Treudler R, Bircher AJ, et al. Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k guideline of the German society for allergology and clinical immunology (DGAKI) in Cooperation with the German dermatological society (DDG), the association of German allergologists (\u00c4DA), the German society for pediatric allergology (GPA), the German contact dermatitis research group (DKG), the German society for pneumology (DGP), the German society of otorhinolaryngology, head and neck surgery, the Austrian society of allergology and immunology (\u00d6GAI), the Austrian society of dermatology and venereology (\u00d6GDV), the German academy of allergology and environmental medicine (DAAU), and the German Documentation center for severe skin reactions (dZh). Allergol Select. 2023;7:122\u201339. https:\/\/doi.org\/10.5414\/ALX02422E.","journal-title":"Allergol Select"},{"key":"5950_CR51","doi-asserted-by":"publisher","unstructured":"Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S-159S. https:\/\/doi.org\/10.1378\/chest.08-0689. Erratum in: Chest. 2008;134(2):473.","DOI":"10.1378\/chest.08-0689"},{"issue":"3","key":"5950_CR52","first-page":"370","volume":"33","author":"H Li","year":"2013","unstructured":"Li H, Wang J, Xiao J, Shi Z. [Efficacy and safety of Fondaparinux versus Enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis]. Nan Fang Yi Ke Da Xue Xue Bao. 2013;33(3):370\u20135. Chinese.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"16","key":"5950_CR53","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","volume":"162","author":"AG Turpie","year":"2002","unstructured":"Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs Enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162(16):1833\u201340. https:\/\/doi.org\/10.1001\/archinte.162.16.1833.","journal-title":"Arch Intern Med"},{"issue":"5","key":"5950_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2165\/00129784-200404050-00005","volume":"4","author":"G Dranitsaris","year":"2004","unstructured":"Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R, et al. Pharmacoeconomic analysis of Fondaparinux versus Enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs. 2004;4(5):325\u201333. https:\/\/doi.org\/10.2165\/00129784-200404050-00005.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"5950_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12891-023-06674-6","volume":"24","author":"T Yang","year":"2023","unstructured":"Yang T, Liu Z, Zhang B, Zhang J, Ma A, Cao D, et al. Comparison of the efficacy of low-molecular-weight heparin and Fondaparinux sodium after total knee arthroplasty: a retrospective cohort study. BMC Musculoskelet Disord. 2023;24(1):552. https:\/\/doi.org\/10.1186\/s12891-023-06674-6.","journal-title":"BMC Musculoskelet Disord"},{"key":"5950_CR56","unstructured":"Arixtra. Fondaparinux sodium. Summary of Product Characteristics. European Medicines Agency. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arixtra#product-details"},{"key":"5950_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/MBC.0b013e328323da86","volume":"20","author":"AGG Turpie","year":"2009","unstructured":"Turpie AGG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of Fondaparinux 1.5\u00a0mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis. 2009;20:114\u201321.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"5950_CR58","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.surge.2021.03.004","volume":"20","author":"F Migliorini","year":"2022","unstructured":"Migliorini F, Maffulli N, Eschweiler J, Knobe M, Tingart M, Betsch M. Tourniquet use during knee arthroplasty: A bayesian network meta-analysis on pain, function, and thromboembolism. Surgeon. 2022;20(4):241\u201351. https:\/\/doi.org\/10.1016\/j.surge.2021.03.004.","journal-title":"Surgeon"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-05950-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-025-05950-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-05950-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:09:38Z","timestamp":1757174978000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-025-05950-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5950"],"URL":"https:\/\/doi.org\/10.1186\/s13018-025-05950-6","relation":{},"ISSN":["1749-799X"],"issn-type":[{"type":"electronic","value":"1749-799X"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a meta-analysis and therefore does not require ethics committee approval or consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors SA and MEF are employed at Viatris. GM is a consultant to Viatris. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"538"}}